Joseph Shulman sold $324k of RYTM
Chief Technical Officer at RHYTHM PHARMACEUTICALS, INC.. 2,815 shares at an average of $115.01, traded Oct 28, 2025, filed Oct 30, 2025.
Score components
- +15RoleOfficer
- +14Trade size$324k at market
- +5Share of holdings soldSold 25% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-25-104437, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 28, 2025 | MOption exercise Common Stock10b5-1 | +2,094 | $27.35 | $57k | 10,603 | Oct 30, 2025 |
| Oct 28, 2025 | MOption exercise Common Stock10b5-1 | +721 | $30.66 | $22k | 11,324 | Oct 30, 2025 |
| Oct 28, 2025 | SOpen-market sale Common Stock10b5-1 | -2,815 | $115.01 | $324k | 8,509 | Oct 30, 2025 |
| Oct 28, 2025 | MOption exercise Stock Options (Right to Buy)derivative10b5-1 | -2,094 | $0.00 | $0 | 12,563 | Oct 30, 2025 |
| Oct 28, 2025 | MOption exercise Stock Options (Right to Buy)derivative10b5-1 | -721 | $0.00 | $0 | 9,748 | Oct 30, 2025 |
Related signals
Other insiders at RHYTHM PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 28Weak | RHYTHM PHARMACEUTICALS, INC. | David P Meeker President and CEO | $5.1M 50,000 shares | -17% | |
| 30Weak | RHYTHM PHARMACEUTICALS, INC. | Hunter C Smith Chief Financial Officer | $6.6M 62,774 shares | -36% | |
| 38Weak | RYTMsell RHYTHM PHARMACEUTICALS, INC. | Christopher Paul German Corporate Controller & CAO | $503k 5,614 shares | -97% | |
| 24Weak | RHYTHM PHARMACEUTICALS, INC. | Hunter C Smith Chief Financial Officer | $806k 7,954 shares | -7% | |
| 23Weak | RHYTHM PHARMACEUTICALS, INC. | Hunter C Smith Chief Financial Officer | $709k 7,071 shares | -6% | |
| 23Weak | RHYTHM PHARMACEUTICALS, INC. | Hunter C Smith Chief Financial Officer | $703k 6,628 shares | -5% | |
| 0Weak | RHYTHM PHARMACEUTICALS, INC. | Pamela J. Cramer Chief Human Resources Officer | $372k 3,350 shares | -14% | |
| 0Weak | RHYTHM PHARMACEUTICALS, INC. | Pamela J. Cramer Chief Human Resources Officer | $352k 3,350 shares | -14% | |
| 33Weak | RHYTHM PHARMACEUTICALS, INC. | Pamela J. Cramer Chief Human Resources Officer | $2.3M 22,866 shares | -57% | |
| 33Weak | RHYTHM PHARMACEUTICALS, INC. | Joseph Shulman Chief Technical Officer | $1.1M 9,748 shares | -53% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.